News · 26 weeks126+40%
2026-04-122026-10-04
Mix5690d
- Other39(70%)
- SEC Filings9(16%)
- Insider3(5%)
- Earnings2(4%)
- Analyst2(4%)
- Leadership1(2%)
Latest news
25 items- PRAbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLCTemab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC)These designations represent the first Breakthrough Therapy Designations (BTDs) for Temab-A and further underscore the strength of AbbVie's ADC portfolio, which now includes four BTDsNORTH CHICAGO, Ill., Oct. 7, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400) in colorectal cancer (CRC)
- SECSEC Form 8-K filed by AbbVie Inc.8-K - AbbVie Inc. (0001551152) (Filer)
- INSIDERSEC Form 4 filed by Director Rapp Edward J4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERSEC Form 4 filed by Director Quaggin Susan E4 - AbbVie Inc. (0001551152) (Issuer)
- PRAbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental VitiligoRINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic therapyPhase 3 Viti-Up-1 and Viti-Up-2 studies show that among patients continuing RINVOQ, the proportions who achieved facial (F-VASI 75) and total body (T-VASI 50) repigmentation continued to increase through week 76Findings from a phototherapy substudy show numerically higher responses with RINVOQ in combination with narrowband ultraviolet B (NB-UVB) phototherapy than with RINVOQ aloneData are being shared in a late-breaking oral presentation at the 2026 European Academy of Dermatology and Venereology (EADV
- PRAbbVie to Host Third-Quarter 2026 Earnings Conference CallNORTH CHICAGO, Ill., Oct. 1, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas incl
- FDAFDA Approval for JUVMO issued to ABBVIE INCSubmission status for ABBVIE INC's drug JUVMO (ORIG-1) with active ingredient TAVAPADON has changed to 'Approval' on 09/25/2026. Application Category: NDA, Application Number: 220415, Application Classification: Type 1 - New Molecular Entity
- PRAbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026Detailed findings, to be presented in a short oral presentation, demonstrated an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of ABBV-295 at dosing intervals beyond weekly administration, including every-other-week and monthly regimensABBV-295 showed meaningful body weight reduction and a favorable tolerability profile at all evaluated dose levels, with topline results announced earlier this year Findings support advancement of ABBV-295 — a non-incretin, amylin-based mechanism — into Phase 2 development for chronic weight managementNORTH CHICAGO, Ill., Sept. 30, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that det
- PRAbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index -75 (EASI-75) response rates versus placebo at Week 16 1The mid-dose regimen was selected for Phase 3 development, supporting further evaluation of the efficacy, safety and dosing profile of zumilokibart 1Zumilokibart is a half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis 1NORTH CHICAGO, Ill., Sept. 30, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Stud
- PRAbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressAbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and psoriatic arthritisNew data for risankizumab and upadacitinib provide further evidence supporting efficacy and safety across diverse patient populations Data evaluating investigational compounds lutikizumab and zumilokibart will also be presented, highlighting AbbVie's ongoing research in additional mechanisms of actionNORTH CHICAGO, Ill., Sept. 30, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced new research across its diverse dermatology portfolio to be presented at the 2026 European Academy of Der
- PRAbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical DevelopmentAbbVie deepens investment in artificial intelligence (AI) by entering into a new collaboration with Valkai to strengthen integrated AI capabilities across clinical developmentAbbVie is committed to integrating AI throughout the drug development journey to advance scientific innovation, strengthen operations and improve outcomes for patientsNORTH CHICAGO, Ill., Sept. 29, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients. Through its partnership with Valkai, AbbVie will deploy purpose-built
- PRU.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's DiseaseJUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1Taken once daily with or without levodopa therapy, JUVMO offers patients a differentiated approach to motor symptom control across the Parkinson's disease continuumApproval is supported by the Phase 3 TEMPO program demonstrating significant improvements in daily functioning, increased "on" time without troublesome dyskinesia and a favorable safety profileNORTH CHICAGO, Ill., Sept. 28, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for t
- PREPKINLY® receives Health Canada Approval for Adults with Follicular LymphomaFollicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 20% to 25% of NHL diagnoses in Canada. Approximately 2,400 to 3,000 Canadians are diagnosed with FL each year. Follicular lymphoma is difficult to treat and often returns.1,2Although treatment can control the disease, follicular lymphoma is generally considered incurable, with patients typically experiencing repeated relapses and progressively shorter remissions over time.3In a Phase 3 study, EPKINLY® in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% compared with rituximab and lenalidomide alone.4,5MONTREAL, Sept. 24, 202
- PRAllergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation ApproachAA Signature: SKIN360 marks the first in a series of assessment protocols addressing patients' evolving aesthetic goals.The program includes provider education and resources to support 96% of patients who are interested in a comprehensive aesthetic consultation.1,2,†IRVINE, Calif., Sept. 22, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the global industry leader in aesthetics, today announced the U.S. launch of AA Signature™. Building on the program's successful international rollout and strong support from health care providers (HCPs), AA Signature is a collection of patient-centric, multimodal consultation approaches that leverage Allergan Medical Institute (AM
- PRAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisRINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more DMARDs1Approval was based on the open-label Phase 1 SELECT-YOUTH study and data from adults with rheumatoid arthritis1,2A new oral solution of RINVOQ was approved for use in patients with pJIA1RINVOQ is currently approved in the European Union for 11 indications across various immune-mediated, inflammatory diseases1NORTH CHICAGO, Ill., Sept. 22, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upa
- PRAbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug DiscoveryMulti-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertiseNORTH CHICAGO, Ill. and SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform, today announced a multi-year collaboration to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-cla
- PRAbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive disorder (MDD) and bipolar I (BP-I) depression These findings provide additional evidence that the benefits observed with VRAYLAR in clinical trials can also be achieved in routine practice, where patients often have more complex treatment needsNORTH CHICAGO, Ill., Sept. 18, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today presented new VRAYLAR® (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder (MDD) and b
- PRAbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) MeetingPlenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM)Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a BCL-2 inhibitor, and combination approaches AbbVie's IMS presence reinforces its strategy to build a differentiated multiple myeloma portfolio across complementary mechanisms designed to address disease complexity and evolving patient needs NORTH CHICAGO, Ill., Sept. 17, 2026
- PRAllergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss MedicationsTwo studies evaluating targeted skincare and dermabrasion approaches will be presented at the 2026 Science of Skin SummitIRVINE, Calif., Sept. 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow® dermabrasion treatments in individuals taking medical weight loss (MWL) medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Presented at the Science of Skin Summit (SSS), Sept. 17-20, 2026, in Austin, Texas, the studies showed statistically significant, investigator-assessed improvements in selected skin qua
- PRAbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario ForumAbbVie and BioLabs University of Toronto are partnering to support the next generation of biotechnology innovators in Ontario.Two winning companies will each receive a year of laboratory space and access to equipment at no cost, as well as access to support and mentorship.Applications open today.TORONTO, Sept. 15, 2026 /CNW/ -- AbbVie (NYSE:ABBV), together with BioLabs University of Toronto, today announced the opening of applications for the AbbVie Biotech Innovators Award during the Life Sciences Ontario Ideas to Action Forum in Toronto. The award aims to support the growth of Ontario's life sciences sector by helping promising early-stage biotechnology companies accelerate the development
- PRAllergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin SummitR&D leaders to lead discussions on the hallmarks of aging, emerging exosome research and evidence-based innovation shaping regenerative aesthetics.A featured SkinMedica® R&D panel on exosomes will introduce the FACTS Principles and examine the scientific questions shaping responsible innovation in this rapidly evolving category.IRVINE, Calif., Sept. 15, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV), will bring its scientific leadership to the 2026 Science of Skin Summit (SSS), taking place Sept. 17-20 in Austin, Texas, through expert programming and on-site education focused on skin longevity, aging biology, regenerative aesthetics and emerging exosome research. Com
- PRAbbVie Declares Quarterly DividendNORTH CHICAGO, Ill., Sept. 10, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable November 16, 2026, to stockholders of record at the close of business on October 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical chall
- PRAbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual MigraineMenstrual migraine is a recurrent, debilitating migraine pattern, with attacks occurring around or during the menstrual period, a predictable time of increased biological vulnerability2,4Atogepant demonstrated statistically significant reductions in migraine days associated with the menstrual period, meeting the primary and all eight ranked secondary endpoints versus placebo in the Phase 3 LUNA study (p<0.0001)1No treatment options are currently approved for menstrual migraine, underscoring the urgent need for care approaches specifically designed for this patient population2,5NORTH CHICAGO, Ill., Sept. 10, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced positive topline results from
- PRAbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple MyelomaEtentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival, hazard ratio 0.40) versus investigator's choice of standard available therapies Etentamig demonstrated low rates of cytokine release syndrome (CRS) and fatal infections with monthly dosing (Q4W) from initiation following a single step-up dose Etentamig's dosing schedule and clinical profile may offer a differentiated treatment option for patients and providersResults support the potential of etentamig, a second-generation BCMA-directed T-cell engager, to enable treatment across a range of settings, inclu
- SECAbbVie Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - AbbVie Inc. (0001551152) (Filer)
ABBV FAQ
7 questionsWhat does AbbVie Inc. do?
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus...Where does ABBV stock trade?
AbbVie Inc. (ABBV) is listed on NYSE.What sector and industry is ABBV in?
AbbVie Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AbbVie Inc. go public?
AbbVie Inc. (ABBV) completed its IPO in 2012.What are analysts saying about ABBV?
AbbVie Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-08-13.What companies are similar to ABBV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), NVS (Novartis AG), AMGN (Amgen Inc.), ABT (Abbott Laboratories). Compare ABBV side-by-side with any of them on Quantisnow.How can I track ABBV on Quantisnow?
Quantisnow aggregates AbbVie Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABBV to receive live email and push alerts on every new disclosure.